Status:
COMPLETED
COREG MR Versus TOPROL-XL On The Lipid Profile Of Normolipidemic Or Mildly Dyslipidemic Patients With Hypertension
Lead Sponsor:
GlaxoSmithKline
Conditions:
Hypertension
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
This study was designed to determine whether treatment with COREG MR is more effective at maintaining a better lipid profile than treatment with TOPROL-XL for hypertension.
Eligibility Criteria
Inclusion
- Documented history of hypertension
- Triglycerides of 120-400 mg/mL
- LDLc levels not requiring lipid lowering medication.
Exclusion
- Has known contraindication to alpha- or beta-blocker therapy.
- Has taken any non-ocular beta-blockers within three months before screening.
- Has Type I or II diabetes.
- Taking lipid lowering medications.
Key Trial Info
Start Date :
January 5 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 28 2007
Estimated Enrollment :
514 Patients enrolled
Trial Details
Trial ID
NCT00273052
Start Date
January 5 2006
End Date
December 28 2007
Last Update
June 25 2018
Active Locations (120)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Birmingham, Alabama, United States, 35205
2
GSK Investigational Site
Birmingham, Alabama, United States, 35209
3
GSK Investigational Site
Birmingham, Alabama, United States, 35211
4
GSK Investigational Site
Birmingham, Alabama, United States, 35242